UNASSIGNED: A systematic literature review (SLR) of real-world studies was conducted to assess the effectiveness of dose escalation of vedolizumab every 8 weeks (Q8W) during maintenance treatment to achieve a response in patients who were either vedolizumab responders experiencing secondary loss of response (SLOR) or non-responders. MEDLINE and EMBASE databases were searched from January 2014 to August 2021.
UNASSIGNED: Screening of SLR outputs identified 72 relevant real-world study publications featuring dose escalation of vedolizumab maintenance therapy. After qualitative review, ten eligible studies (9 articles, 1 abstract) were identified as reporting clinical response and/or clinical remission rates following escalation of intravenous vedolizumab 300 mg Q8W maintenance dosing to every 4 weeks (Q4W) maintenance dosing in adult patients with UC/CD (≥10 patients per study). Overall, 196/395 (49.6%) patients with IBD had a response within 54 weeks of vedolizumab maintenance dose escalation. Although definitions for clinical response/remission varied across the 10 studies, clinical response rates after escalated vedolizumab Q8W maintenance dosing ranged from 40.0% to 73.3% (9 studies) and from 30.0% to 55.8% for remission (4 studies) over a range of 8 to <58 weeks\' follow-up.
UNASSIGNED: This synthesis of real-world effectiveness data in vedolizumab-treated patients with IBD indicates that approximately half were able to achieve or recapture clinical response after escalating vedolizumab maintenance dosing.
UNASSIGNED:进行了真实世界研究的系统文献综述(SLR),以评估维多珠单抗在维持治疗期间每8周(Q8W)剂量递增的有效性,以在维多珠单抗反应者经历继发性反应丧失(SLOR)或无反应者中实现反应。
UNASSIGNED:SLR输出的筛选确定了72篇相关的真实世界研究出版物,其特征是维多珠单抗维持治疗的剂量递增。
UNASSIGNED:这项对接受维多珠单抗治疗的IBD患者的真实世界有效性数据的合成表明,在逐步增加维多珠单抗维持剂量后,大约一半能够实现或重新获得临床反应。